| abstract |
The present invention concerns the field of cancer, and in particular to oncogene-driven metabolic alterations which can simultaneously influence multiple metabolic pathways, thus generating unique cancer phenotypes. The present invention relates to a pharmaceutical kit for the treatment of cancer, particularly to the combination of therapeutic treatment of glycolysis/PI3K and of glutamine metabolism targets, using anti-cancer therapeutic agents showing enhanced anti-cancer effects. |